Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) subsidiaries applied for the renewal of its drugs under China's centralized drug procurement, according to a Shanghai bourse filing on Thursday.
More than 20 products were proposed for renewal as the previous procurement agreements are about to expire.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.